Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced myopathies.

Bernard Bannwarth1

  • 1Department of Rheumatology, Groupe Hospitalier Pellegrin, 33076 Bordeaux Cedex, France. bernard.bannwarth@u-bordeaux2.fr

Expert Opinion on Drug Safety
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis.

Joint bone spine·2020
Same author

Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.

Joint bone spine·2018
Same author

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.

Joint bone spine·2017
Same author

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Annals of the rheumatic diseases·2017
Same author

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

Expert opinion on pharmacotherapy·2017
Same author

Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?

Drugs·2017
Same journal

Trigger tool methodologies in hospital settings: reappraising their role in pharmacovigilance and digital safety surveillance.

Expert opinion on drug safety·2026
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
See all related articles

Drug-induced myopathies range from mild symptoms to severe conditions, often reversible upon drug withdrawal. Recognizing drug-induced muscle disorders is crucial for patient management and recovery.

Area of Science:

  • Pharmacology
  • Neurology
  • Toxicology

Background:

  • Drug-induced muscle disorders present a wide clinical spectrum.
  • An increasing number of medications are implicated as myotoxic.
  • Iatrogenic causes should be considered in patients with muscle symptoms.

Purpose of the Study:

  • To review the clinical spectrum and categories of drug-induced myopathies.
  • To emphasize the importance of considering drug-induced myopathy in differential diagnosis.
  • To highlight the reversibility of these conditions upon drug cessation.

Main Methods:

  • Literature review of drug-induced myopathies.
  • Categorization of myopathies based on clinical and histopathological features.
  • Discussion of causative agents and individual susceptibility.

Related Experiment Videos

Main Results:

  • Drug-induced myopathies are classified into five major categories: necrotizing, inflammatory, mitochondrial, corticosteroid, and neuromyopathies.
  • Specific drug classes are associated with distinct myopathic features (e.g., lipid-lowering drugs with necrotizing myopathies, antiretroviral nucleoside analogues with mitochondrial myopathies).
  • Risk factors and preventive measures are identified for certain drug-induced myopathies, such as statin-induced myopathies.

Conclusions:

  • Drug-induced myopathies are often reversible after discontinuing the causative agent.
  • Clinical and histopathological findings vary depending on the drug and patient factors.
  • Early identification and management of drug-induced muscle disorders are essential for favorable outcomes.